Boston Scientific Co. (NYSE:BSX) Shares Acquired by Nordea Investment Management AB

Nordea Investment Management AB boosted its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 6.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 119,535 shares of the medical equipment provider's stock after buying an additional 7,540 shares during the period. Nordea Investment Management AB's holdings in Boston Scientific were worth $10,713,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in BSX. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in Boston Scientific by 4.4% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 4,119,399 shares of the medical equipment provider's stock valued at $345,205,000 after acquiring an additional 173,034 shares during the last quarter. HWG Holdings LP acquired a new position in shares of Boston Scientific in the 2nd quarter valued at $482,000. Principal Financial Group Inc. grew its holdings in shares of Boston Scientific by 5.9% during the 3rd quarter. Principal Financial Group Inc. now owns 2,010,441 shares of the medical equipment provider's stock worth $168,475,000 after purchasing an additional 111,724 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Boston Scientific by 0.9% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,456,741 shares of the medical equipment provider's stock worth $289,675,000 after purchasing an additional 30,636 shares during the last quarter. Finally, Intech Investment Management LLC raised its holdings in Boston Scientific by 153.5% in the 3rd quarter. Intech Investment Management LLC now owns 197,387 shares of the medical equipment provider's stock valued at $16,541,000 after buying an additional 119,525 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on BSX shares. Royal Bank of Canada lifted their price target on shares of Boston Scientific from $95.00 to $98.00 and gave the company an "outperform" rating in a research report on Thursday, October 24th. Truist Financial boosted their target price on Boston Scientific from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Wednesday, December 18th. Wells Fargo & Company raised their price target on Boston Scientific from $98.00 to $100.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 11th. Evercore ISI boosted their price objective on Boston Scientific from $82.00 to $90.00 and gave the company an "outperform" rating in a report on Tuesday, October 1st. Finally, Citigroup raised their target price on Boston Scientific from $98.00 to $107.00 and gave the company a "buy" rating in a report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $95.96.

Insider Activity at Boston Scientific

In other news, EVP John Bradley Sorenson sold 4,119 shares of the company's stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total value of $370,792.38. Following the sale, the executive vice president now directly owns 35,319 shares in the company, valued at $3,179,416.38. This represents a 10.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Edward J. Ludwig sold 4,877 shares of Boston Scientific stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total value of $446,879.51. Following the completion of the sale, the director now directly owns 39,398 shares of the company's stock, valued at approximately $3,610,038.74. This represents a 11.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 29,989 shares of company stock worth $2,702,261 over the last 90 days. Company insiders own 0.50% of the company's stock.

Boston Scientific Stock Performance

Shares of NYSE:BSX traded up $3.89 during midday trading on Thursday, hitting $95.88. The stock had a trading volume of 10,744,330 shares, compared to its average volume of 5,469,267. Boston Scientific Co. has a 1 year low of $58.09 and a 1 year high of $97.13. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The stock has a 50 day moving average price of $89.73 and a two-hundred day moving average price of $83.67. The company has a market capitalization of $141.31 billion, a PE ratio of 79.24, a P/E/G ratio of 2.67 and a beta of 0.80.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.04. The company had revenue of $4.21 billion for the quarter, compared to analysts' expectations of $4.04 billion. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The firm's quarterly revenue was up 19.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.50 EPS. As a group, equities analysts predict that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.